טוען...
Geographic Variation in Rosiglitazone Use Surrounding FDA Warnings in the Department of Veterans Affairs
BACKGROUND: Geographic variation in the use of prescription drugs, particularly those deemed harmful by the FDA, may lead to variation in patient exposure to adverse drug events. One such drug is the glucose-lowering drug rosiglitazone, for which the FDA issued a safety alert on May 21, 2007, follow...
שמור ב:
| הוצא לאור ב: | J Manag Care Spec Pharm |
|---|---|
| Main Authors: | , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Academy of Managed Care Pharmacy
2015
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4861222/ https://ncbi.nlm.nih.gov/pubmed/26679970 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18553/jmcp.2015.21.12.1214 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|